Drugdocs | Alecensa

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Alecensa

Chemical Name	alectinib
Dosage Form	Capsule (oral; 150 mg)
Drug Class	Kinase inhibitors
System	Respiratory
Company	Hoffmann-La Roche
Approval Year	2015

Indication

For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Alecensa (alectinib) Prescribing Information	2018	Genentech USA, Inc., a Member of the Roche Group, South San Francisco, CA

Document Title	Year	Source
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer.	2018	NICE

Document Title	Year	Source
Brigatinib and alectinib for alk rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: a systematic review and network meta-analysis.	2020	Cancers
ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.	2020	PLoS One
The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.	2018	OncoTargets and Therapy